Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Real-world outcomes suggest that the reassuring safety and impressive downstaging effect of neoadjuvant chemoimmunotherapy seen in clinical trials can be reproduced in the general population with non-small cell lung cancer. Further study to understand the impact of perioperative chemoimmunotherapy in the real-world setting is justified.
Authors
- Daniel J. Boffa (ORCID: https://orcid.org/0000-0001-5471-8833)
- Giorgio Caturegli (ORCID: https://orcid.org/0000-0001-6508-7096)
- Benjamin J. Resio (ORCID: https://orcid.org/0000-0002-9522-7181)
- Maureen Canavan (ORCID: https://orcid.org/0000-0001-9410-3542)
- Michał F. Kamiński (ORCID: https://orcid.org/0000-0002-9714-6457)
- Oluwaseun Ayoade
Institutions
- Yale University (US)
Publication Details
- Journal
- JTCVS Open
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.xjon.2025.09.016
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00